Virtual Library

Start Your Search

I. Barjakarevic

Author of

  • +

    Poster Display Session (ID 63)

    • Event: ELCC 2017
    • Type: Poster Display Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1
    • +

      29P - Baseline characteristics of participants in pl-208: A multi-center trial of the prolung test™ (Transthoracic Bioconductance Measurement) as an adjunct to CT chest scans for the risk stratification of patients with pulmonary lesions suspicious for lung cancer (ID 334)

      12:30 - 13:00  |  Author(s): I. Barjakarevic

      • Abstract

      Lung cancer screening with low dose CTs shows numerous indeterminate pulmonary lesions (IPLs). Followup evaluation entail additional radiation (full dose CT/PET) or invasive biopsies. Alternative, novel adjunctive risk-stratification pathways are needed. Volume-averaged thoracic bioconductance, is a non-invasive technology measured transcutaneously by ProLung’s Electro-Pulmonary Nodule Scan (EPNS). A single center study had demonstrated potential to risk stratify such lesions.[1] with sensitivity/specificity of 90%/92% respectively and ROC >0.90. We present interim patient data of PL-208, a pivotal multicenter EPNS validation study.

      This is IRB approved and prospectively enrolled IPNs being evaluated. It is a two-phase study consisting of 350 subjects, 200 in the algorithm stabilization phase and 150 subjects in a subsequent algorithm validation phase. EPNS is performed within 60 days of the CT and pre tissue biopsies. In this prospective study, all study subjects & investigators are blinded to the EPNS results.

      We present data on the initial 133 subjects in the table comparing data between the earlier feasibility study FML204[1] and PL208. 46(35%) subjects were asymptomatic; the rest had symptoms leading to imaging. Diagnoses include: 84 (63%) lung cancers, 4 (3%) non-primary lung cancers, 20 (15%) benign by biopsy, and 25 (19%) benign by CT follow-up.

      PL-208 cohort has a similar gender and age distribution to the PL204 feasibility study using EPNS as a risk-stratifying tool in evaluating suspicious IPLs. PL-208 includes asymptomatic nodules detected during LDCT screening, and hence more subjects with small T1a IPLs (17% Vs 7%), but overall a majority of subjects have IPNs < 3 cm (59%/56%). Of LCs diagnosed, 38%/41% are in stages I/II. [1]Yung et al. Transcutaneous Computed Bioconductance Measurement. J Thorac Oncol 2012; 7:681–9.\r\nTable: 29PComparison FML-204 and PL-208 patient characteristics\r\n

      Age Mean(range)64 (34-80)65 (22-85)
      Male (%)22 (54%)68 (51%)
      Symptomatic41 (100%)87 (65%)
      COPD diagnosis19 (46%)27 (20%)
      NODULE FEATURES\r\n\r\n
      Solitary/multiple17(41%)/24 (59%)45 (34%)/88 (66%)
      0-10 mm (T1a)2 (7%)23 (17%)
      11-20 mm (T1b)13 (32%)35 (26%)
      21-30 mm (T1c)7 (17%)21 (16%)
      31-50 mm (T2a)9 (22%)25 (19%)
      > 50 mm (T2b/c)8 (20%)22 (17%)
      Solid37 (90%)111 (83%)
      Part solid/GGO3 (7%)/1 (2%)13 (10%)/9 (7%)
      Benign by biopsy/CT-fu9 (22%)/3 (7%)20 (15%)/25 (19%)
      Small cell lung cancer2 (5%)10 (8%)
      Adenocarcinoma20 (49%)51 (38%)
      Squamous cell carcinoma6 (15%)17 (13%)
      Carcinoid1 (2%)6 (5%)
      Non-lung malignancy0 (0%)4 (3%)
      I11 (38%)20 (24%)
      II1 (3%)12 (14%)
      III6 (21%)23 (27%)
      IV11 (38%)20 (24%)
      Other0 (0%)9 (11%)

      Clinical trial identification:

      Legal entity responsible for the study:


      R.C. Yung: Conducted study with ProLung (corporate) sponsorship of study. Lead author also on ProLung Advisory Board, have received consultation fees and travel support (to meetings). Have been offered stock options. D. Ost: Conducted study with ProLung (corporate) sponsorship of study. Have received consultation fees on Advisory Board. M. Simoff, C. Reddy, A. Goyal, I. Barjakarevic: Conducted study with ProLung (corporate) sponsorship of study. M. Garff: Employee of ProLungDx. K. Larson: Employee of ProLung. J. O\'Driscoll: Chief Medical Officer and member of the Board of Directors for ProLungDx. S. Makani: Funded corporate sponsored research from ProLungDx.